AI Article Synopsis
- This method uses Schwartz's reagent to selectively add to azlactones, enabling the creation of functionalized α-amino aldehydes quickly and effectively.
- The reactions occur at room temperature and reach completion in just 2 minutes, resulting in good to high isolated yields.
- Additionally, the process is robust, tolerating sensitive functional groups, and an excess of reagent can yield a highly functionalized allylic alcohol with an 86% yield.
Article Abstract
Highly chemoselective addition of Schwartz's reagent to widely available azlactones is described. This method allows the preparation of challenged functionalized α-amino aldehydes, in good to high isolated yields at room temperature, after only 2 min reaction. The presence of sensitive functionalities or electronic factors does not compromise the potential of the method. The use of an excess of the reducing reagent gave a very functionalized allylic alcohol derivative in 86% yield.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.joc.7b00820 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Zirconium(IV)-Catalysed Hydrosilylation of Organic Carbonates and Polycarbonates Household Wastes into Alcohol Derivatives.
Chemistry
January 2025
Centre CEA Paris-Saclay: Commissariat a l'Energie Atomique et aux Energies Alternatives Centre de Saclay, IRAMIS Institute, CEA - Saclay, 91190, Gif-Sur-Yvette, FRANCE.
The Schwartz's reagent Cp2Zr(H)Cl is a well known stoichiometric reagent for the reduction of unsaturated organic molecules but it has rarely been used in catalytic transformations. Herein, we describe the reduction of a variety of organic carbonates using the catalyst Cp2Zr(H)Cl in combination with Me(MeO)2SiH (DMMS) as reductant. This method was further applied to the reductive depolymerization of some polycarbonate materials and yielded silylated alcohols and diols in mild conditions.
View Article and Find Full Text PDFCharacterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study.
Clin Biochem
January 2025
Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address:
Introduction: The GENCOV study sought to evaluate serological differences between individuals with differing COVID-19 severity and outcomes. We assessed the SARS-CoV-2 antibody response of GENCOV participants cross-sectionally 1-, 6-, and 12-months following COVID-19 diagnosis to identify patient factors associated with more robust and durable humoral immune responses.
Materials And Methods: COVID-19 patients and a control cohort of vaccinated infection-naïve participants were recruited at hospital sites across the Greater Toronto Area in Ontario, Canada.
In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death.
Int J Mol Sci
October 2024
Research Laboratory in Applied Metabolic Engineering, Department of Chemical Engineering, Polytechnique Montréal, Centre-Ville Station, P.O. Box 6079, Montréal, QC H3C 3A7, Canada.
Ovarian cancer presents a dire prognosis and high mortality rates, necessitating the exploration of alternative therapeutic avenues, particularly in the face of platinum-based chemotherapy resistance. Conventional treatments often overlook the metabolic implications of cancer, but recent research has highlighted the pivotal role of mitochondria in cancer pathogenesis and drug resistance. This study delves into the metabolic landscape of ovarian cancer treatment, focusing on modulating mitochondrial activity using methylene blue (MB).
View Article and Find Full Text PDF[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases.
Eur J Radiol
December 2024
Weill Cornell Medicine, Department of Neurological Surgery, New York, NY, USA.
Objective: Our purpose was to describe our initial institutional experience using dedicated brain [18F]-Fluoroestradiol (FES) PET/CT or PET/MRI in the management of patients with estrogen-receptor-positive (ER+) breast cancer brain metastases (BCBM), and compare to [18F]-Fluorodeoxyglucose (FDG) PET and MRI.
Materials & Methods: Patients with biopsy-proven ER+ disease and MRI findings of suspected new, progressive, or recurrent BCBM were included in this retrospective study. Clinical and demographic data were collected.
Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP-1 Drug.
Laryngoscope
February 2025
Department of Otolaryngology-Head & Neck Surgery, University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee, U.S.A.
To report a case of a patient undergoing GLP-1 receptor agonist therapy in which increased FDG uptake in brown adipose tissue (BAT) mimicked metastatic head and neck cancer on PET/CT imaging. A 61-year-old female with Class III obesity presented with a right-sided neck mass after significant weight loss following the use of the GLP-1 receptor agonist, Semaglutide. PET/CT revealed FDG uptake in the right level II lymph node and extensive BAT uptake throughout the neck and mediastinum, complicating the diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!